Jean-François Yale
McGill University Health Centre
EndocrinologyType 2 diabetesInsulinDiabetes mellitusMedicine
What is this?
Publications 130
#1Michael TsoukasH-Index: 1
#2Joanna Rutkowski (McGill University)H-Index: 1
Last. Ahmad Haidar (McGill University)H-Index: 22
view all 9 authors...
Background: FreeStyle Libre is a factory-calibrated, continuous, 14-day, glucose sensor. Little is known about the accuracy of FreeStyle Libre as a function of sensor age. Methods: We assessed the ...
#1Ahmad Haidar (McGill University)H-Index: 22
#2Michael Tsoukas (MUHC: McGill University Health Centre)H-Index: 1
Last. Laurent Legault (MUHC: McGill University Health Centre)H-Index: 16
view all 10 authors...
OBJECTIVE The rapid insulin-alone artificial pancreas improves glycemia in type 1 diabetes but daytime control remains suboptimal. We propose two novel dual-hormone artificial pancreas systems. RESEARCH DESIGN AND METHODS We conducted a randomized crossover trial comparing a rapid insulin-alone artificial pancreas with rapid insulin-and-pramlintide and with regular insulin-and-pramlintide artificial pancreas systems in adults with type 1 diabetes. Participants were assigned to the interventions ...
1 CitationsSource
#1Ahmad HaidarH-Index: 22
#2Jean-François YaleH-Index: 29
Last. Bruce A. PerkinsH-Index: 45
view all 12 authors...
#1David R. Owens (Swansea University)H-Index: 52
#2T. S BaileyH-Index: 1
Last. Geremia B. Bolli (University of Perugia)H-Index: 49
view all 5 authors...
Abstract Aim Second-generation basal insulin analogues (e.g. insulin degludec, insulin glargine 300 U/mL), were designed to further extend the duration of insulin action and reduce within-day and day-to-day variability, and consequently hypoglycaemia risk, versus earlier long-acting basal insulins. This review examines the pharmacokinetic/pharmacodynamic characteristics of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL), and their influence on clinical outcomes. Methods Ava...
#1Lawrence A. Leiter (St. Michael's Hospital)H-Index: 71
#2Alice Y.Y. Cheng (St. Michael's Hospital)H-Index: 9
Last. Anatoly Langer (St. Michael's Hospital)H-Index: 39
view all 14 authors...
Abstract Objectives To describe the clinical histories and management of adults with type 2 diabetes who were not reaching their target glycated hemoglobin (A1C) levels and to identify barriers to achieving therapeutic goals. Methods Practice assessment surveys and practice audits were completed by 88 primary care physicians (PCPs) in the Diabetes Mellitus Assessment of Clinical managemenT In ONtario (DM-ACTION) program and by 56 diabetes specialists in the Diabetes Mellitus IMproving PAtient Ca...
1 CitationsSource
#1John Mancini (UBC: University of British Columbia)H-Index: 53
#2Alice Y. Cheng (U of T: University of Toronto)H-Index: 2
Last. Jean-François Yale (MUHC: McGill University Health Centre)H-Index: 29
view all 15 authors...
Abstract A sea change in the management of diabetes is occurring with the publication of clinical trials showing unequivocal cardiovascular (CV) protection through the use of certain antihyperglycemic agents. This change is similar to the change that occurred when lipid lowering with statins was first shown to have CV benefits, an event necessitating changes in training and the proactive treatment of lipids by CV specialists. As was the case then, many CV specialists currently feel poorly equipp...
#1Jean-François Yale (MUHC: McGill University Health Centre)H-Index: 29
#2Vanita R. Aroda (Brigham and Women's Hospital)H-Index: 14
Last. Robert RitzelH-Index: 14
view all 11 authors...
Abstract Aim Older people with type 2 diabetes (T2DM) are at an increased risk of hypoglycaemia and its consequences. However, efficacy and safety data for basal insulin therapy are limited in these individuals. This patient-level meta-analysis assessed the treatment effects of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with T2DM ≥ 65 years old. Methods Data were pooled for patients randomised to receive Gla-300 or Gla-100 in the Phase 3a, treat-to-target ED...
2 CitationsSource
#1Robyn L. HouldenH-Index: 16
#2Lori BerardH-Index: 12
Last. Jean-François YaleH-Index: 29
view all 5 authors...
#1Ronald GoldenbergH-Index: 14
#2Peter Assimakopoulos (McGill University)H-Index: 2
Last. Jean-François Yale (MUHC: McGill University Health Centre)H-Index: 29
view all 5 authors...